American Society of Hematology

SHERPA: Blue

People

  1. Zelenetz
    Zelenetz
  2. Thompson
    Thompson
  3. Abdel-Wahab
    Abdel-Wahab
  4. Palomba
    Palomba
  5. Tallman
    Tallman
  6. Park
    Park
  7. Geyer
    Geyer
  8. Giralt
    Giralt
  9. Kumar
    Kumar
  10. Perales
    Perales

Groups

  1. Adult Leukemia (94)
  2. Center for Hematologic Malignancies (94)
  3. Department of Medicine (94)
  4. Hematologic Malignancies, Division of (94)
  5. Hematology-Oncology Fellows (43)
  6. Lymphoma (22)
  7. GME, Medicine (15)
  8. Graduate Medical Education (15)
  9. Executive Committee, Center for Hematologic Malignancies (7)
  10. GSK Faculty (7)
Search Within
  1. "Anthony Mato"
Formats
  1. Meeting Abstract (76)
  2. Journal Article (11)
  3. Research Letter (4)
  4. Review (2)
  5. Editorial (1)
Groups
  1. Adult Leukemia (94)
  2. Center for Hematologic Malignancies (94)
  3. Department of Medicine (94)
  4. Hematologic Malignancies, Division of (94)
  5. Hematology-Oncology Fellows (43)
  6. Lymphoma (22)

More Groups

People
  1. Anthony Mato (94)
  2. Lindsey Roeker (40)
  3. Andrew Zelenetz (17)
  4. Meghan Thompson (15)
  5. Maria Palomba (7)
  6. Omar Abdel-Wahab (7)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (4)
  4. 2022 (19)
  5. 2021 (19)
  6. 2020 (17)

More Years

Publications
  1. Blood (82)
  2. Blood Advances (10)
  3. Hematology-American Society of Hematology Education Program (2)

Results (94)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
    Research Letter

    Shanafelt, T. D.; Wang, X. V.; Hanson, C. A.; Paietta, E.; O’Brien, S.; Barrientos, J.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Hypertension treatment for patients receiving ibrutinib: A multicenter retrospective study
    Journal Article

    Samples, L.; Voutsinas, J.; Fakhri, B.; Khajavian, S.; Spurgeon, S.; Stephens, D.; Skarbnik, A.; Mato, A.; Broome, C.; Gopal, A.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world prognostic testing and treatment patterns in CLL/SLL: Results from 1462 patients in the informCLL registry
    Research Letter

    Mato, A. R.; Ghosh, N.; Sharman, J. P.; Brander, D.; Gutierrez, M.; Huang, Q.; Wu, L. H.; Young, A.; Upasani, S.; Naganuma, M.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Journal Article

    Roeker, L. E.; DerSarkissian, M.; Ryan, K.; Chen, Y.; Duh, M. S.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
    Journal Article

    Seymour, J. F.; Byrd, J. C.; Ghia, P.; Kater, A. P.; Chanan-Khan, A.; Furman, R. R.; O'Brien, S.; Brown, J. R.; Munir, T.; Mato, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-314: A phase III open-label, randomized study of pirtobrutinib (LOXO-305) versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Woyach, J. A.; Wierda, W. G.; Coombs, C. C.; Lewis, K. L.; Gribben, J. G.; Escalon, M. P.; Ceccarelli, M.; Wu, X.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Enitociclib (VIP152/formerly BAY1251152) is a selective and active CDK9 inhibitor : Preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Shadman, M.; Mato, A. R.; Batlevi, C. L.; Flinn, I. W.; Gutierrez, M.; Uemura, M.; Stevens, D. A.; Morillo, D.; Byrd, J. C.; Frigault, M. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save